## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8388800

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	

#### **CONVEYING PARTY DATA**

Name	Execution Date
KONRAD REJDAK	11/22/2023

### **RECEIVING PARTY DATA**

Name:	CHORD THERAPEUTICS SA	
Street Address:	15 AVENUE DE SECHERON	
City:	GENEVA	
State/Country:	SWITZERLAND	
Postal Code:	1202	

#### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	16632245

#### **CORRESPONDENCE DATA**

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Email:** request@slwip.com

Correspondent Name: SCHWEGMAN LUNDBERG & WOESSNER, P.A.

Address Line 1: PO BOX 2938

Address Line 4: MINNEAPOLIS, MINNESOTA 55402-0938

ATTORNEY DOCKET NUMBER: 1260.036US1		
NAME OF SUBMITTER: KERRI WRIGHT		
SIGNATURE:	/Kerri Wright/	
DATE SIGNED:	01/18/2024	

#### **Total Attachments: 5**

source=1260036US1RecordationCS#page1.tif source=1260036US1RecordationCS#page2.tif source=1260036US1RecordationCS#page3.tif source=1260036US1RecordationCS#page4.tif source=1260036US1RecordationCS#page5.tif

PATENT 508341608 REEL: 066169 FRAME: 0834

# RECORDATION FORM COVER SHEET PATENTS ONLY

Form PTO-1595 (Rev. 6-18) OMB No. 0651-0027 (exp. 10/31/2024) U.S. Department of Commerce United States Patent and Trademark Office

To the Director of the U.S. Patent and Trademark Office: Please reco		
1. Name of conveying party(ies):	2. Name and ad	dress of receiving party(ies):
Konrad Rejdak	Name:	Chord Therapeutics SA
Additional name(s) of conveying party(ies) attached?	Street Address:	15 avenue de Secheron
[ ]Yes [X]No	City:	Geneva
3. Nature of conveyance/Execution Date(s):	State/Province:	
Execution Date(s): November 22, 2023	Zip:	1202
[X] Assignment [ ] Merger	Country:	Switzerland
[ ] Security Agreement [ ] Change of Name [ ] Joint Research Agreement [ ] Government Interest Assignment [ ] Executive Order 9424, Confirmatory License [ ] Other	*	(s) & address(es) attached?
4. Application number(s) or patent number(s): [ ] This docu A. Patent Application No.(s) Serial No. 16/632,245		ath/Declaration (37 CFR 1.63)  3. Patent No.(s)
Additional numbers attached? [ ]Yes [X]No		
5. Name and address of party to whom correspondence concerning document should be mailed:		of applications and patents involved: 1  CFR 1.21(h) & 3.41): \$0.00
Name: Monique M. Perdok  Address: Schwegman Lundberg & Woessner, P.A. P.O. Box 2938 Minneapolis, Minnesota 55402  Phone Number: (612) 373-6905  Docket Number: 1260.036US1  Email Address: request@slwip.com	0743 []Enclosed [] None reaffecting t  8. Payment Info	equired (government interest not itle)
9. Signature:		
/ Monique Perdok Monique M. Perdok/Reg. No. 42,989	/	Jan 18, 2024
Name of Person Signing	Signature	Date
Total number of pages including	g cover sheet, attach	ments, and documents: 5

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to: Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

#### PATENT ASSIGNMENT

WHEREAS, I, Konrad REJDAK, have made an invention(s), which invention(s) is described in an application(s) for Letters Patent, which application(s) is listed in the attached Schedule; and

WHEREAS, Chord Therapeutics SA, in succession from the transformation of Chord Therapeutics S.a.R.L., of AVENUE DE SECHERON 15, 1202 GENEVA, SWITZERLAND, a Company organized and existing under the laws of SWITZERLAND (hereinafter "Company") is desirous of acquiring, and entitled by agreement, contract, or operation by law, to acquire the entire right, title and interest in and to the invention(s) and in and to the application(s) and any Letters Patent that may be granted therefor;

Now, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the undersigned have sold, assigned and transferred, and/or do hereby sell, assign and transfer unto Company, its lawful successors and assigns, the full, exclusive and worldwide right to the invention(s) and the entire right, title and interest in, to and under the application(s) and any and all Letters Patent that may be granted on the application(s), any and all priority applications and Letters Patent thereof, and any and all applications and Letters Patent claiming priority to the application(s), including any and all divisions or continuations thereof, any and all renewals, substitutes, reissues, reexaminations and extensions thereof, in the United States of America, in the territorial possessions of the United States of America, and equivalents thereto in any country foreign to the United States of America, including full right to claim for any such applications all benefits and priority rights under any applicable convention, the same to be held and enjoyed by Company, its lawful successors and assigns as fully and entirely as the same would have been held by the undersigned had this assignment not been made.

The undersigned hereby authorize and request the Commissioner of Patent and Trademarks of the United States of America and respective Patent Office officials in any country foreign to the United States of America to issue said Letters Patent to Company as the assignee of our entire right, title and interest in, to and under the same, or to Company's lawful successors and assigns.

The undersigned hereby agree for ourselves and for our heirs, executors and administrators, to execute any lawful document and to testify as to any material fact or thing which Company, its lawful successors and assigns may deem necessary in order to secure unto itself, its lawful successors and assigns the full right, title and interest in and to, and the full enjoyment of, the invention(s) or any part thereof, the application(s) and any and all Letters Patent, the same to be done without any further consideration.

The undersigned hereby warrant and represent that I/we have not entered, nor will enter, into any assignment, contract, or understanding in conflict herewith.

12

**PATENT** 

REEL: 066169 FRAME: 0836

IN TESTIMONY WHEREOF, I	hereby set my hand this 22 day of November 2023	
Inventor Signature:	Horred Refolete	
Inventor Name:		
Witness 1:		
I attest that on this da	ay Konrad RE3DAK did sign above in my presence of his own free will.	
Witness Signature:	<u>Barbaro Rejolah</u>	
Witness Name:	BARBARA REJDAK	s is literari - Official
	isti aktoria nga mili bersada kanamahan tuna ana Jamis ya Manamahan matemakan	lijashsa
Date:	<u>22 NOV 2023</u>	
	nscholer Staff ab ad achter arb rackmaktka alaker akk akk akk alaker alaker	ffto-xi
Witness 2:		
I attest that on this do	By Konrad REJDAK did sign above in my presence of his own free will.	
Witness Signature: <a></a>	stanisla Rejelak	
Witness Name:		filosofi (p.)
Date: Yes Joseph	22 NOV 2023	
	appropriate and the second second control of the second second control of the second s	

PATENT REEL: 066169 FRAME: 0837

IN TESTIMONY WHEREOF, I hereby set my hand on behalf of CHC	ORD THERAPEUTICS SA, this 616 day
of DECEMBER 2013	
Calmin management	
Signature:	
Cédric Hyde	
Name and Title: Authorized Representative	
and the same of th	
Signature:	
t annual Cartilla	
Laurent Bastide	
Name and Title Authorized Representative	
Witnesses: I attest that on this day, the above persons o	n behalf of CHORD THERAPEUTICS SA
did sign above in my presence of their own free will.	
was asyn sawe, none production or over one conservation	
1 10. V ~	
Witness Signature: Aug LL Comment	
	<del></del>
,	
Witness Name: TOSODE PERMINI	
TOO ICCO TESTON	
8	
Date: 06/12/23//	
Date:	••••••
// /	
Witness Signature:	
Witness Name: A NULTE ARLT	
ANTHEOD MORREY A CACE SANGE XXXX S. V. LANDAR	
Date: 6 december 2023	
Date: V CKUNDOV ONUZ >	<del></del>

**REEL: 066169 FRAME: 0838** 

#### SCHEDULE

Application No.	Country	Filing Date	Tille	
1711800.1	GB	21 JUL 2017	USE OF CLADRIBINE FOR TREATIN AUTOIMMUNE NEUROMUSCULAR DISEASE	
PCT/GB2018/051801	2018/051801 WO 28 JUN 2018		USE OF CLADRIBINE FOR TREATING AUTOIMMUNE NEUROMUSCULAR	
			DISEASE	

tendra desarro in tradicio de la constante de la constante de la constante de desarrollar de desarrollar de de

PATENT

PATENT REEL: 066169 FRAME: 0839

~4 ~

**RECORDED: 01/18/2024**